Opsumit: Withdrawal of the application to change the marketing authorisation



Janssen-Cilag International NV withdrew its application for the use of Opsumit in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH), a condition that causes high blood pressure in the lungs.

The company withdrew the application on 8 November 2019.

  • List item

    Questions and answers on the withdrawal of application to change the marketing authorisation for Opsumit (macitentan) (PDF/122.7 KB)

    First published: 15/11/2019

  • Key facts

    Product number
    Date of issue of market authorisation valid throughout the European Union (if applicable)
    International non-proprietary name (INN) or common name
    • macitentan
    Active substance
    • Macitentan
    Date of withdrawal
    Company making the application
    Janssen-Cilag International N V  
    Withdrawal type

    All documents

    Related information on withdrawals

    The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').

    How useful was this page?

    Add your rating